期刊文献+

细胞色素P4503A7*1c基因多态性与蒙古族妇女骨质疏松的关系

The relationship between CYP3A7 polymorphisms and density in menopausal Mongolian women
下载PDF
导出
摘要 目的探讨CYP3A7基因多态性与内蒙古地区蒙古族绝经妇女骨密度的关系。方法应用聚合酶链反应.限制性片段长度多态(PCR-RFLP)测定185名内蒙古地区健康绝经期妇女经SspI酶切后CYP3A7基因多态性,同时用双能X线吸收法测定前臂骨密度。结果基因型频率分布依次为正常组TT型84.4%,TG15.0%,GG0.7%,骨质疏松组TT型71.1%,TG26.3%,GG2.6%,等位基因频率正常组T为91.8%,G为8.2%;骨质疏松组T为84.2%,G为15.8%。通过协方差分析,调整年龄、身高、体重、BMI,结果显示,CYP3A7基因型与左前臂BMD有相关性(P〈0.05)。骨量减少组和骨量正常组间等位基因频率具有显著性差异(P〈0.05),基因型频率无显著性差异(P〉0.05)。结论CYP3A7基因型与蒙古族妇女前臂BMD有关联(P〈0.05),可作为预测骨质疏松发生的危险性因素。 Objective To explore the relationship between CYP3A7 polymorphisms and bone mineral density in menopausal Mongolian women in Inner Mongoha. Methods CYP3A7 polymorphisms defined by the SspI restriction enzyme using polymerase chain reaction-restriction fragment length polymorphism in 185 healthy menopausal Mongolian women in Inner Mongolia, forearm BMD were measured by dual energy X-ray absorptiometry. Results The frequency distribution of CYP3A7 genotype was normal group: TIP 84.4%, TG 15.0%, GG 0.7%; Osteoporosis group: TT 71.1%, TG 26.3 %, GG 2.6 %. CYP3A7 allele frequency were normal group : T 91.8 %, G 8.2%; Osteoporosis group:T 87%, G 13%, Covarianee analysis showed significant association between CYP3A7 genotype and BMD at left forearm in all groups after adjusting age, body height, body weight and BMI. There was statistical significance between osteopenia group and control group in allele genes, but no statistical significance in genotype frequency. Conclusions Among Mongolian women in Inner Mongolia, CYP3A7 polymorphisms was associated with bone mineral density (P 〈 0.05). It can be used to predict the risk of osteoporosis.
出处 《中国骨质疏松杂志》 CAS CSCD 2009年第2期92-95,共4页 Chinese Journal of Osteoporosis
关键词 蒙古族妇女 骨质疏松症 CYP3A7基因多态性 骨密度 Mongolian women Osteoporosis CYP3A7 polymorphisms Bone mineral density
  • 相关文献

参考文献13

  • 1Bacsi K, Kosa JP, Borgulya G, et al. CYP3A7 * 1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcif Tissue Int, 2007,80 (3) : 154-159.
  • 2Bacsi K, Kosa J, Lazary A, et al. Impact of CYP3A7 * 1C polymorphism on bone mineral content in postmenopausal women. Orvosi Hetil Orvosi Hetilap A CYP3A7 * 1C-Polimorfizmus Hatasa a Csont Asvanyanyag-Tartalmara Posztmenopauzas Nokben, 2007, 148 (27) : 1273-1280.
  • 3Smit P, Van Schalk R, der Van Werf, et al. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab Journal of Clinical Endocrinology and Metabolism, 2005,90(9) :5313-5316.
  • 4Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. Journal of Pharmacology and Experimental Therapeutics, 2003, 307(2): 573-582.
  • 5Greuet J, Pichard L, Bonfils C, et al. The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture. Biochemical and Biophysical Research Communications, 1996, 225(2) : 689-694.
  • 6Kuehl Peter. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphie CYP3A5 expression. Nature Genetics, 2001,27(4) : 383-391.
  • 7Burk O, Tegude H, Koch I, et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem Journal of Biological Chemistry, 2002, 277(27) :24280- 24288.
  • 8程春雷,游雪甫.细胞色素P4503A研究进展[J].国外医药(抗生素分册),2004,25(3):124-127. 被引量:17
  • 9Burk O, Wojnowski L. Cytochrome P450 3A and their regulation. Naunyn-Schmiedeberg's Arch Pharmacol Naunyn-Schmiedeberg's Archives of Pharmacology, 2004,369 ( 1 ) : 105-124.
  • 10Stevens JC. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discovery Today, 2006, 11(9-10) : 440-445.

二级参考文献16

  • 1Balley DG,Dresser GK,Kreeft JH,et al.Grapefrut-feledipine interaction:effect of unprocessed fruit and robable ingredients [J].Clin Pharmacol Ther,2000,68:468
  • 2Gegg CR.Drug interaction and anti-infective therapies[J].Am J Med,1999,106:227
  • 3Nelson DR,Koymans L,kamataki T,et al.P450 superfamily:update on new sequences,gen mapping,accession numbers and nomenclature[J].Pharmacogenetics,1996,6 (1):1
  • 4Drcss GK,Spence JD,Bailey DG.Pharmcokinetic-pharmacodynamic cousequences and clinical relevance of cytochrome P4503A4 inhibition [J].Clin Pharmacokenet,2000,38(1):41
  • 5Commins CL,Wu CY,Benet LZ.Sex-related differences in the clearance of cytochrome P4503A4 substrate maybe caused by Pglycoprotein[J].Clin Pharmacol Ther,2002,72 (5):474
  • 6Murray M,Cantrill E,Metha I,et al.Impaired expression of microsomal cytochrome P450 2C11 in choline-deficient rat liver during the development of cirrhosis[J].J Pharmacol Exp Ther,1992,261:373
  • 7Lytton SD,Helander A,Zhiang-Gouillon ZQ,et al.Autoantibodies against cytochrome P-4502E1 and P-4503A in alcoholics[J].Mol Pharmacol ,1999,55:223
  • 8Thummel KE,Shen DD,Podoll TD,et al.Use of midazolam as a human cytochrome P4503A probe:in vivo-in vitro correlation in liver trensplant patients[J].J Pharmaco Exp Ther ,1994,271:549
  • 9Iwahori T,Matsuura T,Maehashe H,et al.CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartifical liver[ J ].Hepatology,2003,37(3):665
  • 10Gibson GG,Plant NJ,Swales KE,et al.Receptor-dependent transcriptional activation of P4503A genes:Inducation Mechanism,Species differences and interindividnal variation in man [J].Xenobiotica,2002,32 (3):165

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部